Emergent BioSolutions Inc. Operating Income Loss

• Emergent BioSolutions Inc. showed an increase of +85.0% in Operating Income Loss from 2023 to 2024.
• This data is from Emergent BioSolutions Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2025.
• XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2009 to 2024), Emergent BioSolutions Inc.'s Operating Income Loss has declined by 370.7%.
• Historical annual values: Fiscal year 2024: -$108.70 million | Fiscal year 2023: -$726.40 million | Fiscal year 2022: -$170.00 million | Fiscal year 2021: $341.40 million | Fiscal year 2020: $433.80 million | Fiscal year 2019: $114.10 million | Fiscal year 2018: $89.80 million | Fiscal year 2017: $124.30 million | Fiscal year 2016: $105.50 million | Fiscal year 2015: $141.51 million | Fiscal year 2014: $89.19 million | Fiscal year 2013: $42.80 million | Fiscal year 2012: $29.97 million | Fiscal year 2011: $32.10 million | Fiscal year 2010: $73.56 million | Fiscal year 2009: $40.15 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026